AlveoGene’s Post

Startups Exploring Diversity in Genetics and Biotechnology Research This week we spotlight startups helping close the diversity gap in healthcare. The journey towards achieving diversity in genetics and biotechnology research is critical and ongoing. Startups like Yemaachi Biotech, Hurone AI and Acclinate are pioneering innovative solutions to address the lack of diversity in genomics, biotechnology, and clinical trial research. Through their groundbreaking technologies, collaborative initiatives, and inclusive approaches, these startups are revolutionising the landscape of healthcare equity and diversity. By Henry Duah Read the full article: https://lnkd.in/ezAhCkVn Get innovation insights from The FutureList weekly. Subscribe to our newsletter here: https://bit.ly/3DVZexv #cancercare #genomics #biotechnology #clinicaltrials #artificialintelligence

🧬 𝗧𝗵𝗿𝗶𝗹𝗹𝗲𝗱 𝘁𝗼 𝗦𝗽𝗲𝗮𝗸 𝗮𝘁 𝗦𝘆𝗻𝗕𝗶𝗼𝗕𝗲𝘁𝗮 𝟮𝟬𝟮𝟰!🧬 🗓️ 𝗗𝗮𝘁𝗲: 𝗠𝗮𝘆 𝟳, 𝟮𝟬𝟮𝟰 ⏰ 𝗧𝗶𝗺𝗲: 𝟭:𝟰𝟱 𝗣𝗠 - 𝟮:𝟯𝟬 𝗣𝗠 𝗣𝗧 📍 𝗟𝗼𝗰𝗮𝘁𝗶𝗼𝗻: 𝗥𝗼𝗼𝗺 𝟮𝟭𝟬𝗖, 𝗦𝗮𝗻 𝗝𝗼𝘀𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗖𝗲𝗻𝘁𝗲𝗿 Hello everyone! Our CEO, Joe Hedley is excited to be a part of this year's SynBioBeta conference, particularly during the session titled "Living the Code: Gene Synthesis Impacts Beyond the Lab." 🔬 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝗢𝘃𝗲𝗿𝘃𝗶𝗲𝘄: Join us as we discuss the transformative world of enzymatic DNA synthesis and its expansive impact on various sectors. We'll discuss not just the technology itself but how it's being applied in groundbreaking ways—from public health efforts to advanced biomanufacturing and beyond. 💡 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀: As the demand for precise genetic tools escalates, understanding the capabilities and potential limitations of current gene synthesis technologies is crucial. Our panel will explore how these innovations can continue to evolve and address real-world challenges effectively. 🌍 𝗘𝗻𝗴𝗮𝗴𝗲 𝗮𝗻𝗱 𝗘𝘅𝗽𝗹𝗼𝗿𝗲: Expect to hear about real-world applications, the hurdles we face in scaling these technologies, and the future potential of gene synthesis. Whether you're a scientist, an entrepreneur, or simply curious about the future of biotechnology, this discussion promises to be enlightening. 👥 𝗟𝗲𝘁’𝘀 𝗖𝗼𝗻𝗻𝗲𝗰𝘁: Looking forward to sharing insights, connecting with fellow innovators, and discussing how we can push the boundaries of what's possible in synthetic biology together. #SynBioBeta2024 #GeneSynthesis #Biotechnology #NunaBio #Innovation Join us! https://lnkd.in/gXnddUE2

Exciting Times for European Biotech! The European biotech landscape is buzzing with innovation and groundbreaking projects! As we steer into the future, we're witnessing remarkable advancements that are set to shape the healthcare and technology sectors. Recently, I came across a news article highlighting the launch of several high-impact biotech projects across Europe. One notable initiative is the comprehensive research into gene editing led by a consortium of biotech firms from the UK, Germany, and France. This project aims to revolutionise treatments for genetic disorders, offering hope to millions. Another milestone is a major collaboration between Nordic countries focusing on sustainable biomanufacturing, which promises to reduce the carbon footprint of pharmaceutical production. These projects not only demonstrate Europe's commitment to scientific excellence but also underline the vision for a healthier, sustainable future. Having spent years in the biotech industry, I can personally attest to the immense potential of these collaborations. They reflect the collective expertise and a shared passion for pushing the boundaries of what's possible. The support from the European Union, in terms of funding and policy frameworks, has been instrumental in accelerating these innovations. It's an inspiring time to be part of this community, and I look forward to seeing the tangible benefits these projects will bring. How do you see these developments shaping the future? Drop your thoughts below! #Biotech #Innovation #EuropeanScience #HRS #Science

In recent years, biotechnology and genomics have surged to the forefront of innovation, transforming industries from healthcare to agriculture. Here's why they’re generating so much buzz: Personalized Medicine: Genomics allows us to understand our DNA on a deeper level, leading to customized treatments that target individual genetic profiles. This promises better patient outcomes and fewer side effects. Biotech for Sustainability: From engineered crops that resist pests to biofuels reducing our carbon footprint, biotech is revolutionizing how we tackle climate change and feed the world sustainably. Breakthroughs in Disease Research: Advances in gene editing technologies like CRISPR are paving the way for groundbreaking treatments for genetic disorders, cancers, and even previously incurable diseases. COVID-19’s Impact: The pandemic highlighted the power of biotechnology, especially in the rapid development of mRNA vaccines, underscoring how biotech can respond to global health crises. Investments on the Rise: With venture capital flowing into biotech startups and research institutions, the pace of innovation is accelerating, making it one of the most exciting fields to watch. As these fields continue to evolve, we’re standing on the brink of discoveries that could reshape life as we know it. 🌍 #Biotech #Genomics #Innovation #Healthcare #Sustainability #FutureOfMedicine #Science #CRISPR #DNA #Trending

"Biotechnology continues to be a driving force in shaping the future of various industries, with a focus on innovation and sustainability. Recent trends in biotechnology include the rise of personalized medicine, gene editing technologies like CRISPR, and the development of bio-based materials for a more sustainable future. The integration of artificial intelligence and big data analytics is also revolutionizing the biotech industry, enabling faster drug discovery and more precise genetic engineering. As biotechnology continues to evolve, it is poised to address some of the most pressing challenges facing society today, from healthcare to environmental sustainability." #LinkedIn #Social #Biotechnology #Innovation #Success #Bioinformatics #Genes #CRISPR #Future

DRIVING INNOVATION IN BIOTECHNOLOGY ... At Breathermae, we are pioneering a new era in biotechnology by integrating advanced bioenergetics and predictive analytics into our platform. Here’s how we are differentiating our approach: 1. Innovative Integration of Bioenergetics: Unlike traditional biotechnology approaches that often focus on genetic and molecular levels, our technology uniquely integrates bioenergetics to predict and manage the onset of disease. This adds a novel dimension to biotechnology, opening new avenues for understanding and influencing health at an energetic level. 2. Advanced Predictive Analytics: We use cutting-edge predictive analytics powered by AI and quantum computing to identify energetic precursors of disease. This allows for earlier interventions than current molecular diagnostics, positioning our technology as a breakthrough in predictive healthcare. 3. Synergy with Existing Biotech Innovations: Our platform complements existing biotech innovations like gene editing and regenerative medicine by providing an additional layer of insight into how these therapies interact with the body’s energetic systems. 4. Scalability and Global Impact: Our approach is scalable across diverse populations and healthcare systems, offering a global impact by providing a preventative healthcare model that can be adopted widely. By aligning with the core objectives of the biotechnology industry, our goal is to not only advance healthcare — but redefine it. Discover how our strategic focus can revolutionize biotech solutions and create unprecedented opportunities for improving patient outcomes. #Biotechnology #Innovation #HealthcareTech #Bioenergetics

“The world of #biotechnology is in the midst of a wave of exciting #research and #clinical advances—from #artificialintelligence-based #drugdiscovery to cell and #genetherapy, to precision #genomeediting and other newer technologies. These advances are driving new therapies for patients and fueling recoveries for the markets that generate capital for the industry, from the venture capital that powers private #startups, to the initial public offerings of more mature companies. In GEN’s flagship virtual event, The State of #Biotech—sponsored exclusively by Cytiva —we proudly host an outstanding group of research and business leaders from industry and academia to discuss the latest research developments, innovations, disruptive technologies and #regulatory changes that will spur biotech forward to bigger and better things, for patients around the world. • An opening keynote with David Altshuler MD, PhD, Executive VP and Chief Scientific Officer of @Vertex Pharmaceuticals • A keynote presentation with John F. Crowley President and CEO of the Biotechnology Innovation Organization (BIO) • Back by popular demand, the co-hosts of the popular Biotech Hangout podcast—Daphne Zohar, Brad Loncar, and Chris Garabedian—review the highs and lows of the biotech space • Atimely discussion on the state of #ai in biotech with industry experts from Google, NVIDIA, and Recursion • A conversation with Tim Harris, author of the new book In Pursuit of Unicorns: A Journey through 50 Years of Biotechnology—a crackling memoir chronicling the history of biotech • Building a path for #CRISPR therapies with Brad Ringeisen, PhD (IGI) and Sadik Kassim, PhD (Danaher) Parallel breakout sessions hosted by Cytiva The State of Biotech is  GEN’s flagship virtual event, following its successful introduction in 2022 and expansion last year. Registration is entirely free.” When: Wednesday, September 11, 2024 Time: 8:00 am PT, 11:00 am ET, 17:00 CEST #lifesciences #researchanddevelopment #stem #scienceandtechnology #science #pharma #biopharma #techbio #likeandshare

Reproducibility surely could be better

Ever wondered what we do at Myllia Biotechnology? Then have a look at this video snippet which I created using Video GPT/ veed.io. Not (yet) perfect, but certainly a good start. And please go to www.myllia.com to learn more about our capabilities!

Science and technology are moving forward quickly, and we at Bayer are excited to be part of this journey. However, the rapid evolution of science and the opportunities these new developments bring also come with challenging ethical questions. To address these challenges, Bayer established a group of external experts, the Bayer Bioethics Council, who tackle complex ethical issues in areas like biotechnology, healthcare, and artificial intelligence. One of the council members is Andreas Kurtz, a professor specializing in stem cell research in Germany. He shares some insights into why considering bioethics is crucial when looking at the potential of regenerative medicine. #Bioethics #Innovation #TeamBayer